New York, September 29 (EFE) .- The American pharmaceutical company Moderna reported on Tuesday that its mRNA-1273 vaccine, for the prevention of covid-19, “can generate neutralizing antibodies in the elderly and older adults at levels comparable to (generated in) young adults “.
The conclusion, based on provisional data, was published in the scientific journal “The New England Journal of Medicine”.
In July, the company announced the start of phase 3 testing of its experimental vaccine against the disease transmitted by the new coronavirus to the general population, involving 30,000 volunteers, and the executive director, Stephen Bancel, said in the middle of the month that it would be possible assess whether the vaccine is effective by October, although he believed that the expected data on the final stage of development is likely to be revealed in November.
“These provisional data from phase 1 suggest that mRNA-1273, our candidate vaccine for the prevention of covid-19, can generate neutralizing antibodies in older and older adults at levels comparable to those of younger adults,” said Tal Zaks, director Moderna doctor, cited in the publication.
“Due to the higher morbidity and mortality of covid-19 in older and older adults, these data give us optimism to demonstrate the protection of mRNA-1273 in this population,” he added.
Moderna explained that this interim analysis evaluated a phase 1 vaccination program involving the inoculation of two doses of mRNA-123, which were administered 28 days apart in 40 patients divided into two groups, one aged 56 to 70, and another 71 years old or more.
Some volunteers received doses of 25 micrograms (µg), and others, 100 µg. Tests carried out one month after the administration of the second dose revealed that the 100 µg dose generated higher neutralizing antibody titers.
The company emphasized that, in general, both doses were well tolerated and did not generate serious side effects.
Moderna cited headaches, myalgia, chills and pain at the injection site as the most common, “most of which were mild to moderate in intensity and of limited duration.
The company also explained that, after the second vaccination, “two serious systemic adverse events occurred”: fever in a participant in the 56 to 70 year old group who received the 25 µg dose and fatigue in a participant in the 70+ year old group. age who received the 100 µg dose.
However, Moderna reported that they “did not reveal any pattern of concern”. EFE
jfu / id